Our Vision

We are pioneering a path to obtain FDA approval for SM-030, which we expect will become the leading targeted topical therapeutic for the treatment of melasma and other hyperpigmentation disorders of the skin.

Our capital efficient approach leveraged decades of combined team experience to run efficient clinical trials at a fraction of industry standard timelines and budgets.

SM-030

DermBiont is advancing targeting topical small molecule, SM-030, for the treatment of melasma and other hyperpigmentation disorders of the skin.